{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T10:04:05Z","timestamp":1779617045726,"version":"3.53.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordination of Higher Education Personnel Improvement","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2017\/14207-7"],"award-info":[{"award-number":["2017\/14207-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2021\/04166-7"],"award-info":[{"award-number":["2021\/04166-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110560","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:42:17Z","timestamp":1749696137000},"page":"110560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Persistent COX-2 upregulation in L-DOPA-induced dyskinesia is unaffected by inhibition with celecoxib"],"prefix":"10.1016","volume":"278","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-7379","authenticated-orcid":false,"given":"Maur\u00edcio","family":"dos Santos Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Del Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110560_bib1","article-title":"Cytokine-mediated differential regulation of cyclooxygenase-2, high mobility group box 1 protein and matrix metalloproteinase-9 expression in fibroblast-like synovial cells","volume":"07","author":"Asmaa","year":"2017","journal-title":"Clin Exp Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neuroscience.2008.07.016","article-title":"Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta","volume":"156","author":"Barnum","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110560_bib4","doi-asserted-by":"crossref","first-page":"18664","DOI":"10.1073\/pnas.1907810116","article-title":"Role of striatal DeltaFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates","volume":"116","author":"Beck","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110560_bib5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/s41467-022-29606-9","article-title":"Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations","volume":"13","author":"Bell","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2025.110560_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/361031a0","article-title":"A synaptic model of memory: long-term potentiation in the hippocampus","volume":"361","author":"Bliss","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2025.110560_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12640-016-9618-4","article-title":"Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson's disease","volume":"30","author":"Bortolanza","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2025.110560_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.nbd.2014.10.017","article-title":"Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease","volume":"73","author":"Bortolanza","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15439","article-title":"Doxycycline and its derivative, COL-3, decrease dyskinesia induced by L-DOPA in hemiparkinsonian rats","author":"Bortolanza","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib10","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0190","article-title":"Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?","volume":"370","author":"Bortolanza","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib11","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0184","article-title":"Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?","volume":"370","author":"Calabresi","year":"2015","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nn.4306","article-title":"Hyperkinetic disorders and loss of synaptic downscaling","volume":"19","author":"Calabresi","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ejn.13482","article-title":"l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?","volume":"45","author":"Carta","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in L-DOPA-induced dyskinesia","volume":"183","author":"Cenci","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110560_bib16","first-page":"2694","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of <scp>L<\/scp> \u2010DOPA\u2010Induced dyskinesia in the unilateral 6\u2010OHDA lesion model of Parkinson's disease in rats and mice","volume":"41","author":"Cenci","year":"2007","journal-title":"Curr Protoc Neurosci"},{"key":"10.1016\/j.neuropharm.2025.110560_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0306-4522(99)00294-8","article-title":"Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment","volume":"94","author":"Cenci","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110560_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson's disease in women and men: what's the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib20","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1152\/jn.2002.87.6.2851","article-title":"Cyclooxygenase-2 regulates prostaglandin E 2 signaling in hippocampal long-term synaptic plasticity","volume":"87","author":"Chen","year":"2002","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/viro.2000.0562","article-title":"NSAID treatment suppresses VSV propagation in mouse CNS","volume":"276","author":"Chen","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.neuropharm.2025.110560_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2009.09.015","article-title":"Contribution of reactive oxygen species to migration\/invasion of human glioblastoma cells U87 via ERK-dependent COX-2\/PGE2 activation","volume":"37","author":"Chiu","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/syn.21941","article-title":"l-DOPA-induced dyskinesia in Parkinson's disease: are neuroinflammation and astrocytes key elements?","volume":"70","author":"Del-Bel","year":"2016","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2025.110560_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0006-8993(97)00630-6","article-title":"Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine","volume":"767","author":"Dluzen","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110560_bib25","article-title":"Contributive role of TNF-alpha to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of Parkinson's disease","volume":"11","author":"Dos Santos Pereira","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109926","article-title":"4\u2032-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: contribution of anti-inflammatory and anti-glutamatergic mechanisms","volume":"251","author":"dos Santos Pereira","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110560_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1045465","article-title":"Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model","volume":"13","author":"Dos Santos Pereira","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/glia.24489","article-title":"The two synthetic cannabinoid compounds 4\u2019-F-CBD and HU-910 efficiently restrain inflammatory responses of brain microglia and astrocytes","volume":"72","author":"Dos Santos Pereira","year":"2024","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110560_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnbeh.2011.00047","article-title":"Unraveling the differential functions and regulation of striatal neuron sub-populations in motor control, reward, and motivational processes","volume":"5","author":"Ena","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib33","doi-asserted-by":"crossref","first-page":"21824","DOI":"10.1073\/pnas.1012071107","article-title":"Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia","volume":"107","author":"Fasano","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110560_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0304-3940(02)00704-8","article-title":"Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra","volume":"329","author":"Feng","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110560_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fnbeh.2011.00071","article-title":"L-DOPA-Induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission","volume":"5","author":"Feyder","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/glia.22956","article-title":"Altered astrocyte morphology and vascular development in dystrophin-Dp71-null mice","volume":"64","author":"Giocanti-Auregan","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110560_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.580311","article-title":"Parkinson's disease: can targeting inflammation Be an effective neuroprotective strategy?","volume":"14","author":"Gundersen","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.2003.021477","article-title":"Chemoprevention of gastric cancer by celecoxib in rats","volume":"53","author":"Hu","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.neuropharm.2025.110560_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106452","article-title":"Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice","volume":"193","author":"Huang","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","article-title":"Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice","volume":"162","author":"Iancu","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110560_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1460-9568.2005.04220.x","article-title":"The acute and the long\u2010term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation","volume":"22","author":"Iravani","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1742-2094-10-45","article-title":"Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide","volume":"10","author":"Kaizaki","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110560_bib44","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0064-17.2017","article-title":"Microglial TNF\u03b1 induces COX2 and PGI2 synthase expression in spinal endothelial cells during neuropathic pain","volume":"4","author":"Kanda","year":"2017","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2025.110560_bib45","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110560_bib46","doi-asserted-by":"crossref","first-page":"9895","DOI":"10.1007\/s11033-020-06033-x","article-title":"Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder","volume":"47","author":"Kumar","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.neuropharm.2025.110560_bib47","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s11064-017-2379-5","article-title":"Neuroprotective activities of spirulina platensis in the 6-OHDA model of Parkinson's disease are related to its anti-inflammatory effects","volume":"42","author":"Lima","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2025.110560_bib48","doi-asserted-by":"crossref","first-page":"18381","DOI":"10.1523\/JNEUROSCI.1875-13.2013","article-title":"\u0394FosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli","volume":"33","author":"Lobo","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib49","first-page":"272","volume":"vol. 96","author":"McAdam","year":"1999"},{"key":"10.1016\/j.neuropharm.2025.110560_bib50","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/jnen\/63.9.901","article-title":"Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases","volume":"63","author":"Minghetti","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib51","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbabio.2010.04.009","article-title":"Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons","volume":"1797","author":"Misiak","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2025.110560_bib52","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/brain\/awl031","article-title":"Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias","volume":"129","author":"Morgante","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110560_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.expneurol.2016.09.013","article-title":"Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease","volume":"286","author":"Mulas","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0306-4522(02)00578-X","article-title":"Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females","volume":"116","author":"Murray","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110560_bib55","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/mds.28215","article-title":"Continuous dopaminergic stimulation as a treatment for Parkinson's disease: current status and future opportunities","volume":"35","author":"Olanow","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110560_bib56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuropharm.2014.08.019","article-title":"Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats","volume":"89","author":"Padovan-Neto","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110560_bib57","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.neuroscience.2009.01.034","article-title":"Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"159","author":"Padovan-Neto","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2025.110560_bib58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neulet.2013.02.015","article-title":"Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB\/deltaFosB expression","volume":"541","author":"Padovan-Neto","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110560_bib59","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.26326","article-title":"Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity","volume":"30","author":"Paolone","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2025.110560_bib60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.biopsych.2005.05.044","article-title":"ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice","volume":"59","author":"Pavon","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110560_bib61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2025.110560_bib62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2007.10.001","article-title":"l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation","volume":"29","author":"Picconi","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.yhbeh.2022.105206","article-title":"Task-specific effects of biological sex and sex hormones on object recognition memories in a 6-hydroxydopamine-lesion model of Parkinson's disease in adult male and female rats","volume":"144","author":"Pinizzotto","year":"2022","journal-title":"Horm. Behav."},{"key":"10.1016\/j.neuropharm.2025.110560_bib65","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00702-018-1874-4","article-title":"Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function","volume":"125","author":"Pisanu","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2025.110560_bib66","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.nbd.2014.08.011","article-title":"Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-gamma agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease","volume":"71","author":"Pisanu","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/jnc.15993","article-title":"The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias","volume":"167","author":"Rentsch","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110560_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104646","article-title":"Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia","volume":"134","author":"Rentsch","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib69","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-2094-1-6","article-title":"Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease","volume":"1","author":"Sanchez-Pernaute","year":"2004","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110560_bib70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1017\/cjn.2023.8","article-title":"Levodopa-induced dyskinesia in Parkinson's disease: plausible inflammatory and oxidative stress biomarkers","volume":"51","author":"Sarkar","year":"2024","journal-title":"Can. J. Neurol. Sci.\/J. Can. Sci. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2018.03.003","article-title":"mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia","volume":"38","author":"Sebastianutto","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2014.09.010","article-title":"Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-\/-) aphakia mice","volume":"73","author":"Solis","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110560_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105439","article-title":"Deciphering the mechanisms of reciprocal regulation or interdependence at the cannabinoid CB1 receptors and cyclooxygenase-2 level: effects on mood, cognitive implications, and synaptic signaling","volume":"155","author":"Stachowicz","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2025.110560_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114729","article-title":"Deciphering the mechanisms of regulation of an excitatory synapse via cyclooxygenase-2. A review","volume":"192","author":"Stachowicz","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib75","first-page":"167","article-title":"The rodenticidal effect of indomethacin: pathogenesis and pathology","volume":"78","author":"Taiwo","year":"2008","journal-title":"Vet. Arh."},{"key":"10.1016\/j.neuropharm.2025.110560_bib76","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ejn.14290","article-title":"Immune system responses in Parkinson's disease: early and dynamic","volume":"49","author":"Tansey","year":"2019","journal-title":"Eur. J. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2025.110560_bib77","first-page":"220","article-title":"The role of eicosanoids in the brain","volume":"17","author":"Tassoni","year":"2008","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"10.1016\/j.neuropharm.2025.110560_bib78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/biof.1035","article-title":"COX-2 in the neurodegenerative process of Parkinson's disease","volume":"38","author":"Teismann","year":"2012","journal-title":"Biofactors"},{"key":"10.1016\/j.neuropharm.2025.110560_bib79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00441-004-0944-0","article-title":"Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation","volume":"318","author":"Teismann","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2025.110560_bib80","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1073\/pnas.0837397100","article-title":"Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration","volume":"100","author":"Teismann","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110560_bib81","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110560_bib82","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1523\/JNEUROSCI.2888-13.2014","article-title":"Striatal cholinergic cell ablation attenuates l-DOPA induced dyskinesia in parkinsonian mice","volume":"34","author":"Won","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib83","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/brain\/aww117","article-title":"Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice","volume":"139","author":"Woodling","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2025.110560_bib84","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1073\/pnas.88.7.2692","article-title":"Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing","volume":"88","author":"Xie","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110560_bib85","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1007\/s12035-015-9355-3","article-title":"Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system","volume":"53","author":"Yagami","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110560_bib86","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0896-6273(93)90192-T","article-title":"Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids","volume":"11","author":"Yamagata","year":"1993","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110560_bib87","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2174\/138161208784480144","article-title":"Cyclooxygenase-2 in synaptic signaling","volume":"14","author":"Yang","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2025.110560_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.614412","article-title":"Circuit mechanisms of L-DOPA-induced dyskinesia (LID)","volume":"15","author":"Yang","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib89","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12031-017-0922-0","article-title":"Celecoxib alleviates memory deficits by downregulation of COX-2 expression and upregulation of the BDNF-TrkB signaling pathway in a diabetic rat model","volume":"62","author":"Yang","year":"2017","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110560_bib90","doi-asserted-by":"crossref","DOI":"10.3791\/57648-v","article-title":"Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ","author":"Young","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuropharm.2025.110560_bib91","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/j.1582-4934.2008.00430.x","article-title":"Cyclooxygenase in normal human tissues--is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?","volume":"13","author":"Zidar","year":"2009","journal-title":"J. Cell Mol. Med."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825002667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:28:18Z","timestamp":1779614898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825002667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":91,"alternative-id":["S0028390825002667"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110560","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent COX-2 upregulation in L-DOPA-induced dyskinesia is unaffected by inhibition with celecoxib","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110560"}}